Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04247815 · ClinicalTrials.gov registry record · Phase 2
Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA
A Phase 2 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT04247815 is a Phase 2 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 25 participants.
The verdict
NCT04247815, a Phase 2 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a Phase 2 study to investigate the safety, tolerability, PK, and PD of ATI-450 plus methotrexate versus methotrexate alone in patients with moderate to severe RA.
Interventions
- DRUG Placebo oral tablet
- DRUG Methotrexate
- DRUG ATI-450
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-03-16 |
| Est. Completion | 2021-02-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04247815
The ClinicalTrials.gov registry entry for NCT04247815 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo oral tablet is the first listed.
NCT04247815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04247815 about?
NCT04247815 is a clinical study titled "Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA". This is a Phase 2 study to investigate the safety, tolerability, PK, and PD of ATI-450 plus methotrexate versus methotrexate alone in patients with moderate to severe RA.
What is the current status of trial NCT04247815?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2020-03-16. Estimated completion is 2021-02-04.
What interventions are being tested in trial NCT04247815?
The interventions under investigation include: Placebo oral tablet (DRUG), Methotrexate (DRUG), ATI-450 (DRUG).
Who is sponsoring clinical trial NCT04247815?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.